Dr. Lisa Bomgaars' focus is on the design of clinical research studies and the understanding and development of new drugs and devices. She assists investigators with the design of clincal protocols testing new treatments and has performed numerous studies of new drugs for the treatment of cancer and blood disorders.
In addition, she has particular expertise in the area of anticoagulation in the setting of mechanical circulation (artificial hearts). She is an expert in clinical research operations and works with the Children's Oncology Group and the Global Hope program in this capacity. She is also the Director of the Research Resources Office at Texas Children's Hospital.
Properly designed clinical research studies allow us to identify the best new therapies for the treatment of our patients. The ultimate goal of Dr. Bomgaars' research is to identify new therapies to improve the survival and lives of children with cancer and hematologic disorders.
Dr. Bomgaars has performed a number of clinical studies that have lead to the use of new drugs in children. Some of these include Protein C Concentrate for children with congenital protein C deficiency, Romiplostim for the treatment of ITP, Clofarabine for the treatment of leukemia, and Depocyte for the treatment of central nervous system leukemia. She also contributed to the design and was an investigator in the first study of a pediatric artificial heart that led to the FDA approval of the Berlin Heart EXCOR Pediatric.
Her work has been published in the Journal of Clinical Oncology, Blood and the New England Journal of Medicine.
New drug development
Novel anticoagulation agents for the treatment of thrombosis
Pharmacogenetically guided warfarin therapy